Regulatory Writing Series #2: Top 5 Regulatory Writing Mistakes That Can Delay FDA Approval—And How to Avoid Them
by Charles Replogle, COO of ScienceDocs
In the life sciences, time lost is often opportunity lost. Regulatory submissions such as INDs, NDAs, and PMAs are not just administrative checkboxes—they are high-stakes, high-scrutiny documents that must be both scientifically sound and regulatory-compliant. Even seasoned teams make costly regulatory writing mistakes that can lead to delays, Requests for Information (RFIs), or Complete Response Letters (CRLs) from the FDA. Below are five of the most common mistakes—and how a professional regulatory writer can help you avoid them.
1. Lack of a Clear, Scientific Narrative
Many companies focus on compiling data, but they miss the importance of telling a coherent scientific story. Regulatory agencies want to understand not just what the data shows, but why your development program makes sense.
A seasoned regulatory writer ensures that the narrative flows logically across all modules of the Common Technical Document (CTD), tying together clinical, nonclinical, and CMC data into a unified justification for your product’s safety and efficacy. This is particularly important in Module 2 summaries (e.g., 2.5 Clinical Overview), where reviewers look for a synthesized, high-level interpretation of detailed data sets.
2. Data Inconsistencies and Integration Failures
A frequent issue is misalignment across documents—numbers that differ between the clinical study report (CSR), the Integrated Summary of Efficacy (ISE), and the statistical analysis plan (SAP). Even minor inconsistencies can raise red flags for regulators and lead to time-consuming information requests.
An experienced regulatory writer conducts cross-document QC and ensures that data points, endpoint definitions, patient populations, and adverse event narratives are consistently represented across all components of your submission.
3. Overuse of Jargon or Ambiguous Language
While scientific precision is critical, excessive use of domain-specific terminology, undefined abbreviations, or vague conclusions can frustrate reviewers and obscure meaning. Regulators are scientists, and they absolutely expect clarity.
A regulatory writer brings both scientific literacy and editorial rigor, ensuring the language is clear, direct, and aligned with regulatory expectations—especially in sections like risk-benefit analysis, safety assessments, and rationale for study design.
4. Structural and Formatting Errors
Each regulatory agency has specific expectations for document structure, content, and formatting. Submissions that do not comply with the FDA’s eCTD format, ICH E3 guidelines for CSRs, or specific regional templates can be rejected outright or flagged for rework.
ScienceDocs regulatory writers stay up to date with evolving regulatory standards and are well-versed in formatting protocols, including heading hierarchies, table presentation, pagination, and hyperlinking—ensuring technical correctness at the structural level.
5. Reactive Rather Than Proactive Writing
Writing should begin before a study starts—not after. Many companies wait until the last minute, leading to disorganized documents, rushed analyses, and inadequate responses to FDA guidance or meeting minutes.
Proactive regulatory writers are involved early in protocol development, pre-IND meetings, and regulatory strategy. They help document decisions, align language across modules, and even contribute to briefing packages and meeting questions. In short, they don’t just write—they guide.
How ScienceDocs Can Help
At ScienceDocs, our regulatory writers are PhDs and senior-level specialists with backgrounds in clinical research, pharmacology, medical devices, and regulatory affairs. We provide full-spectrum support—everything from protocol development to CTD assembly—and work closely with your scientific and clinical teams to minimize risk and accelerate timelines. Please fill out our Quote Form and let us know a bit about you and your regulatory writing needs!